476060.KQ
Onconic Therapeutics
KOE · Healthcare · Biotechnology · KR
KRW 15,120.00
+3.56%Margins
Gross margin
54.4%
EBITDA margin
23.1%
EBIT margin
21.1%
Net margin
29.5%
FCF margin
20.1%
28.3%
Return on equity
26.1%
Return on assets
20.1%
Return on invested capital
0.91x
Asset turnover
KRW 16.8B
Cash from operations
KRW 1.4K
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026